Journal of International Medical Research, 2022 Omalizumab is used for the treatment of persistent severe allergic asthma in adults and children. However, some patients remain symptomatic even after omalizumab treatment. In bronchial asthma, chronic inflammation of the bronchial wall causes thickening
Mitsuru Tsuge +3 more
doaj +1 more source
Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]
, 2019 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus +3 more
core +1 more source
Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps [PDF]
, 2019 Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a signifcant impairment in quality of life.
Cavaliere, Carlo +7 more
core +1 more source
Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]
, 2020 Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C +3 more
core +1 more source
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
World Allergy Organization Journal, 2019 Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up.
Ivan Cherrez-Ojeda +15 more
doaj +1 more source
Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
Pulmonology, 2021 Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a ...
A. Arrobas +4 more
doaj +3 more sources
Allergy & Rhinology, 2018 Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Abhishek Kavati +8 more
doaj +1 more source
Prototype of running clinical trials in an untrustworthy environment using blockchain. [PDF]
, 2019 Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system.
Bhattacharya, Sanchita +2 more
core +3 more sources
Treatment of estrogen-induced dermatitis with omalizumab [PDF]
, 2019 In 1945, Drs Bernhard Zondek and Yehuda Bromberg demonstrated intradermal treatment with estrone and estradiol benzoate induced urticarial lesions in some patients.1 Fifty years later, Shelley et al,2 who introduced the concept of progesterone dermatitis
Baker, William H. +5 more
core +1 more source
Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab
Allergology International, 2014 Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizumab, the IgE subfraction in complex with ...
Reiko Ito +9 more
doaj +1 more source